Literature DB >> 24037848

Methods for radiolabelling of monoclonal antibodies.

Vladimir Tolmachev1, Anna Orlova, Karl Andersson.   

Abstract

The use of radionuclide labels allows to study the pharmacokinetics of monoclonal antibodies, to control the specificity of their targeting and to monitor the response to an antibody treatment with high accuracy. Selection of label depends on the processing of an antibody after binding to an antigen, and on the character of information to be derived from the study (distribution of antibody in the extracellular space, target occupancy or determination of sites of metabolism). This chapter provides protocols for labelling of antibodies with iodine-125 (suitable also for other radioisotopes of iodine) and with indium-111. Since radiolabelling might damage and reduce the immunoreactive fraction and/or affinity of an antibody, the methods for assessment of these characteristics of an antibody are provided for control.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24037848     DOI: 10.1007/978-1-62703-586-6_16

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  10 in total

1.  (125)I-labeled anti-bFGF monoclonal antibody inhibits growth of hepatocellular carcinoma.

Authors:  Peng-Hui Hu; Lan-Hong Pan; Patrick Ting-Yat Wong; Wen-Hui Chen; Yan-Qing Yang; Hong Wang; Jun-Jian Xiang; Meng Xu
Journal:  World J Gastroenterol       Date:  2016-06-07       Impact factor: 5.742

2.  Experimental Therapy of HER2-Expressing Xenografts Using the Second-Generation HER2-Targeting Affibody Molecule 188Re-ZHER2:41071.

Authors:  Yongsheng Liu; Anzhelika Vorobyeva; Anna Orlova; Mark W Konijnenberg; Tianqi Xu; Olga Bragina; Annika Loftenius; Erica Rosander; Fredrik Y Frejd; Vladimir Tolmachev
Journal:  Pharmaceutics       Date:  2022-05-20       Impact factor: 6.525

3.  Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors.

Authors:  Anzhelika Vorobyeva; Olga Bragina; Mohamed Altai; Bogdan Mitran; Anna Orlova; Alexey Shulga; Galina Proshkina; Vladimir Chernov; Vladimir Tolmachev; Sergey Deyev
Journal:  Contrast Media Mol Imaging       Date:  2018-06-06       Impact factor: 3.161

4.  Comparison of tumor‑targeting properties of directly and indirectly radioiodinated designed ankyrin repeat protein (DARPin) G3 variants for molecular imaging of HER2.

Authors:  Anzhelika Vorobyeva; Alexey Sсhulga; Elena Konovalova; Rezan Güler; Bogdan Mitran; Javad Garousi; Sara Rinne; John Löfblom; Anna Orlova; Sergey Deyev; Vladimir Tolmachev
Journal:  Int J Oncol       Date:  2019-02-11       Impact factor: 5.650

5.  Possibility of cancer-stem-cell-targeted radioimmunotherapy for acute myelogenous leukemia using 211At-CXCR4 monoclonal antibody.

Authors:  Noboru Oriuchi; Miho Aoki; Naoyuki Ukon; Kohshin Washiyama; Chengbo Tan; Saki Shimoyama; Ken-Ichi Nishijima; Kazuhiro Takahashi; Hiroshi Ito; Takayuki Ikezoe; Songji Zhao
Journal:  Sci Rep       Date:  2020-04-22       Impact factor: 4.379

6.  Radionuclide Molecular Imaging of EpCAM Expression in Triple-Negative Breast Cancer Using the Scaffold Protein DARPin Ec1.

Authors:  Anzhelika Vorobyeva; Ekaterina Bezverkhniaia; Elena Konovalova; Alexey Schulga; Javad Garousi; Olga Vorontsova; Ayman Abouzayed; Anna Orlova; Sergey Deyev; Vladimir Tolmachev
Journal:  Molecules       Date:  2020-10-14       Impact factor: 4.411

7.  Feasibility of Imaging EpCAM Expression in Ovarian Cancer Using Radiolabeled DARPin Ec1.

Authors:  Anzhelika Vorobyeva; Elena Konovalova; Tianqi Xu; Alexey Schulga; Mohamed Altai; Javad Garousi; Sara S Rinne; Anna Orlova; Vladimir Tolmachev; Sergey Deyev
Journal:  Int J Mol Sci       Date:  2020-05-07       Impact factor: 5.923

8.  Comparative evaluation of affibody- and antibody fragments-based CAIX imaging probes in mice bearing renal cell carcinoma xenografts.

Authors:  Javad Garousi; Fokko J Huizing; Anzhelika Vorobyeva; Bogdan Mitran; Ken G Andersson; Charles Dahlsson Leitao; Fredrik Y Frejd; John Löfblom; Johan Bussink; Anna Orlova; Sandra Heskamp; Vladimir Tolmachev
Journal:  Sci Rep       Date:  2019-10-17       Impact factor: 4.379

9.  Benefit of Later-Time-Point PET Imaging of HER3 Expression Using Optimized Radiocobalt-Labeled Affibody Molecules.

Authors:  Sara S Rinne; Charles Dahlsson Leitao; Zahra Saleh-Nihad; Bogdan Mitran; Vladimir Tolmachev; Stefan Ståhl; John Löfblom; Anna Orlova
Journal:  Int J Mol Sci       Date:  2020-03-13       Impact factor: 5.923

10.  Effective targeting of intact and proteolysed CDCP1 for imaging and treatment of pancreatic ductal adenocarcinoma.

Authors:  Thomas Kryza; Tashbib Khan; Simon Puttick; Chao Li; Kamil A Sokolowski; Brian Wc Tse; Tahleesa Cuda; Nicholas Lyons; Madeline Gough; Julia Yin; Ashleigh Parkin; Elena I Deryugina; James P Quigley; Ruby H P Law; James C Whisstock; Andrew D Riddell; Andrew P Barbour; David K Wyld; Paul A Thomas; Stephen Rose; Cameron E Snell; Marina Pajic; Yaowu He; John D Hooper
Journal:  Theranostics       Date:  2020-03-04       Impact factor: 11.556

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.